IPCXRLOW SIGNALFINANCIAL10-Q

IPCXR's quarterly 10-Q filing shows routine updates for a recently public SPAC with improved operating losses and reduced current liabilities.

This is a standard quarterly filing transition from September 2025 to March 2026 for a Special Purpose Acquisition Company (SPAC) that went public in April 2025. The company continues to have no operations as expected for a SPAC seeking acquisition targets, with financial changes reflecting normal quarterly variations in expenses and cash management.

Comparing 2026-05-14 vs 2025-11-14View on EDGAR →
FINANCIAL ANALYSIS

Operating losses improved significantly by 77% from -$2.8M to -$627K, indicating better expense control in the current quarter. Current liabilities decreased by 32% while cash and equivalents declined by 26%, suggesting the company is managing its cash burn rate effectively. Overall, the financial picture shows a SPAC operating within normal parameters while searching for acquisition opportunities, with controlled expenses and adequate liquidity position.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+77.4%
-$2.8M-$627K

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Current Liabilities
Balance Sheet
-32%
$458K$312K

Current liabilities reduced — improved short-term financial position and working capital health.

Cash & Equivalents
Balance Sheet
-25.9%
$1.1M$835K

Cash decreased 25.9% — monitor burn rate and upcoming capital needs.

Current Assets
Balance Sheet
-17.4%
$1.3M$1.1M

Current assets declined 17.4% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2026-05-14
PRIOR — 2025-11-14
ADDED
Financial Statements 1 Condensed Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 2025 1 Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2026, and 2025 (Unaudited) 2 Condensed Consolidated Statements of Changes in Shareholders Deficit for the Three Months Ended March 31, 2026, and 2025 (Unaudited) 3 Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025 (Unaudited) 4 Notes to Condensed Consolidated Financial Statements (Unaudited) 5 Item 2.
On April 28, 2025, the Company consummated the Initial Public Offering of 25,300,000 units at $ 10.00 per unit, which includes the full exercise of the underwriter s over-allotment option, therefore the 1,100,000 founder shares are no longer subject to forfeiture.
(2) On October 10, 2024, in connection with a recapitalization, the Company issued the Sponsor an additional 1,916,667 Class B ordinary shares for no additional consideration, following which the Sponsor holds 7,666,667 Class B ordinary shares.
III NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2026 (Unaudited) NOTE 1.
As of March 31, 2026, the Company had not commenced any operations.
+7 more — sign up free →
REMOVED
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
III NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) NOTE 1.
As of September 30, 2025, the Company had not commenced any operations.
III NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025 (Unaudited) Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of an aggregate of 740,000 units (the Private Placement Units and together with the Public Units, the Units ), to the Sponsor and Cantor Fitzgerald Co., the representative of the underwriters ( Cantor ), at a price of $ 10.00 per unit, or $ 7,400,000 in the aggregate.
Transaction costs amounted to $ 17,305,941 , consisting of $ 4,400,000 of cash underwriting fee, $ 12,045,000 of deferred underwriting fee, and $ 860,941 of other offering costs.
+7 more — sign up free →
SIGNAL HISTORY — IPCXR
2025-11
2026-05
HighMediumLow
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →
MORE IPCXR SIGNALS
MEDIUMIPCXR's operating losses improved meaningfully in the quarter as the SPAC continues its se...
2025-11-14